Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 4.97
FOLD's Cash to Debt is ranked higher than
66% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. FOLD: 4.97 )
FOLD' s 10-Year Cash to Debt Range
Min: 4.97   Max: No Debt
Current: 4.97

Equity to Asset 0.28
FOLD's Equity to Asset is ranked higher than
52% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. FOLD: 0.28 )
FOLD' s 10-Year Equity to Asset Range
Min: 0.28   Max: 0.84
Current: 0.28

0.28
0.84
F-Score: 1
Z-Score: -4.17
M-Score: 19.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -17680.72
FOLD's Operating margin (%) is ranked lower than
51% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. FOLD: -17680.72 )
FOLD' s 10-Year Operating margin (%) Range
Min: -17680.72   Max: -11.42
Current: -17680.72

-17680.72
-11.42
Net-margin (%) -16427.82
FOLD's Net-margin (%) is ranked lower than
51% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. FOLD: -16427.82 )
FOLD' s 10-Year Net-margin (%) Range
Min: -16427.82   Max: -10.2
Current: -16427.82

-16427.82
-10.2
ROE (%) -130.34
FOLD's ROE (%) is ranked higher than
54% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. FOLD: -130.34 )
FOLD' s 10-Year ROE (%) Range
Min: -150.08   Max: -9.14
Current: -130.34

-150.08
-9.14
ROA (%) -46.75
FOLD's ROA (%) is ranked higher than
61% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. FOLD: -46.75 )
FOLD' s 10-Year ROA (%) Range
Min: -1350.9   Max: -7.69
Current: -46.75

-1350.9
-7.69
ROC (Joel Greenblatt) (%) -1557.79
FOLD's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. FOLD: -1557.79 )
FOLD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2144.32   Max: -167.08
Current: -1557.79

-2144.32
-167.08
Revenue Growth (%) -30.70
FOLD's Revenue Growth (%) is ranked higher than
63% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. FOLD: -30.70 )
FOLD' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -2.6
Current: -30.7

EBITDA Growth (%) -14.80
FOLD's EBITDA Growth (%) is ranked higher than
70% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. FOLD: -14.80 )
FOLD' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 82.8
Current: -14.8

0
82.8
EPS Growth (%) -16.30
FOLD's EPS Growth (%) is ranked higher than
72% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. FOLD: -16.30 )
FOLD' s 10-Year EPS Growth (%) Range
Min: -85.2   Max: 59.5
Current: -16.3

-85.2
59.5
» FOLD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

FOLD Guru Trades in Q2 2013

Chuck Royce 715,700 sh (New)
Jim Simons 173,644 sh (+155.95%)
RS Investment Management 2,522,419 sh (-2.98%)
» More
Q3 2013

FOLD Guru Trades in Q3 2013

Jim Simons 302,600 sh (+74.26%)
RS Investment Management 2,794,439 sh (+10.78%)
Chuck Royce 515,700 sh (-27.94%)
» More
Q4 2013

FOLD Guru Trades in Q4 2013

Jim Simons 399,401 sh (+31.99%)
RS Investment Management 2,797,339 sh (+0.1%)
Chuck Royce 355,700 sh (-31.03%)
» More
Q1 2014

FOLD Guru Trades in Q1 2014

Charles Brandes 48,100 sh (New)
RS Investment Management 2,816,739 sh (+0.69%)
Chuck Royce 313,700 sh (-11.81%)
Jim Simons 121,000 sh (-69.7%)
» More
» Details

Insider Trades

Latest Guru Trades with FOLD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2014-03-31 New Buy$2.04 - $3.08 $ 3.8353%48100
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.90
FOLD's P/B is ranked higher than
66% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. FOLD: 7.90 )
FOLD' s 10-Year P/B Range
Min: 0.64   Max: 8.38
Current: 7.9

0.64
8.38
P/S 256.41
FOLD's P/S is ranked higher than
63% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. FOLD: 256.41 )
FOLD' s 10-Year P/S Range
Min: 0.71   Max: 290
Current: 256.41

0.71
290
EV-to-EBIT -3.15
FOLD's EV-to-EBIT is ranked higher than
63% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. FOLD: -3.15 )
FOLD' s 10-Year EV-to-EBIT Range
Min: 0.1   Max: 0.8
Current: -3.15

0.1
0.8
Current Ratio 7.84
FOLD's Current Ratio is ranked higher than
85% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. FOLD: 7.84 )
FOLD' s 10-Year Current Ratio Range
Min: 3.46   Max: 18.26
Current: 7.84

3.46
18.26
Quick Ratio 7.84
FOLD's Quick Ratio is ranked higher than
86% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. FOLD: 7.84 )
FOLD' s 10-Year Quick Ratio Range
Min: 3.46   Max: 18.26
Current: 7.84

3.46
18.26

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 12.80
FOLD's Price/Tangible Book is ranked higher than
67% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. FOLD: 12.80 )
FOLD' s 10-Year Price/Tangible Book Range
Min: 0.96   Max: 6.9
Current: 12.8

0.96
6.9
Price/Median PS Value 23.90
FOLD's Price/Median PS Value is ranked higher than
64% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. FOLD: 23.90 )
FOLD' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 29.38
Current: 23.9

0.09
29.38
Forward Rate of Return (Yacktman) -19.96
FOLD's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. FOLD: -19.96 )
FOLD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 86.4   Max: 734.4
Current: -19.96

86.4
734.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AM6.Germany
Amicus Therapeutics, Inc. was incorporated on February 4, 2002 in Delaware. The Company is a Biopharmaceutical Company focused on the discovery, development and commercialization of orally-administered, small molecule drugs known as pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. The Company is focused on the development of pharmacological chaperones as monotherapies and in combination with enzyme replacement therapy (ERT), the current standard of treatment for Fabry and other lysosomal storage diseases. In 2012, it is advancing two monotherapy programs for genetic diseases: Migalastat HCl for patients with Fabry disease identified as having alpha-galactosidase A (alpha-Gal A) mutations amenable to chaperone therapy, and AT3375 for Parkinson's disease in Gaucher disease carriers and potentially the broader Parkinson's population. Its pharmacological chaperone-ERT combination programs for 2012 include: Migalastat HCl co-administered with ERT for patients with Fabry disease receiving ERT treatment with any genetic mutation, AT2220 (duvoglustat HCl) co-administered with ERT for Pompe disease, AT3375 and afegostat tartrate co-administered with ERT for Gaucher disease, and Several new, undisclosed pharmacological chaperone programs focused on the combination of chaperones with ERTs for additional lysosomal storage diseases. The Company's novel approach to the treatment of human genetic diseases consists of using pharmacological chaperones that selectively bind to the target protein; increasing the stability of the protein and helping it fold into the correct three-dimensional shape. Its product candidate, migalastat HCl for Fabry disease, is in late Phase 3 development. It is developing and commercializing migalastat HCl with an affiliate of GlaxoSmithKline PLC (GSK) pursuant to a License and Collaboration Agreement entered into in October 2010. Its partnership with GSK allows it to utilize GSK's significant expertise in clinical, regulatory, commercial and manufacturing matters in the development of migalastat HCl. In addition, it is conducting another Phase 2 co-administration study evaluating its pharmacological chaperone AT2220 (duvoglustat HCl) co-administered with ERT in Pompe patients. Unlike migalastat HCl, it owns rights to the development of AT2220. In addition to its patents and trade secrets, The Company owns certain trademarks in the U.S. and/or abroad, including A AMICUS THERAPEUTICS & design and AMICUS THERAPEUTICS. Its competitors include Sanofi Aventis, Shire, Actelion, Ltd. and Protalix Biotherapeutics. The Company's product candidates, including migalastat HCl, and the activities associated with their development and commercialization, including their testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to
» More Articles for FOLD

Headlines

Articles On GuruFocus.com
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 09 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 07 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 04 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 08 2009 
iwillbeback note on FOLD Sep 03 2008 

More From Other Websites
Edelman's Perceptive Advisors Buying Amicus Therapeutics Ahead Of Phase III Data Release Jul 23 2014
4 Key Positive Biotech Stock Catalysts Coming Very Soon Jul 17 2014
Can the Uptrend Continue for Amicus (FOLD)? Jul 07 2014
AMICUS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jul 02 2014
Amicus Therapeutics (FOLD) Is Today's Perilous Reversal Stock Jul 02 2014
Strength Seen in Amicus Therapeutics, Inc. (FOLD) as Stock Rallies 19.46% Jul 02 2014
Amicus Up on Migalastat Study Update Jul 01 2014
Why Amicus Therapeutics (FOLD) Stock Continues To Gain Jul 01 2014
Amicus Extending Rally On Upgrades Jul 01 2014
Amicus Therapeutics Provides Updates and Final Analysis Plan for Phase 3 Fabry Monotherapy Study 012 Jun 30 2014
Amicus Therapeutics - Long Opportunity With Asymmetric Upside Potential And Near-Term Catalyst Jun 27 2014
AMICUS THERAPEUTICS INC Files SEC form 8-K/A, Change in Directors or Principal Officers, Financial... Jun 23 2014
AMICUS THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 16 2014
Amicus Therapeutics Still A "Show Me" Story Jun 12 2014
Amicus Therapeutics, Inc. (FOLD) in Focus: Stock Rises 8.13% Jun 04 2014
Amicus Therapeutics (FOLD) Soars: Stock Up 10% May 30 2014
Amicus Therapeutics' Management Presents at UBS Global Healthcare Conference (Transcript) May 21 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide